Bosentan (bosentan): Reviews and patient testimonials

Bosentan 125 mg Film-coated Tablets

Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:

• Primary (idiopathic and heritable) PAH

• PAH secondary to scleroderma without significant interstitial pulmonary disease

• PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology

Some improvements have also been shown in patients with PAH WHO functional class II.

Bosentan is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

Bosentan 62.5 mg Film-coated Tablets

Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:

• Primary (idiopathic and heritable) PAH

• PAH secondary to scleroderma without significant interstitial pulmonary disease

• PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology

Some improvements have also been shown in patients with PAH WHO functional class II.

Bosentan is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

Bosentan Accord 125 mg film-coated tablets

Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:

• Primary (idiopathic and heritable) pulmonary arterial hypertension

• Pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease

• Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology

Some improvements have also been shown in patients with pulmonary arterial hypertension WHO functional class II.

Bosentan tablets are also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

Bosentan Accord 62.5 mg film-coated tablets

Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:

• Primary (idiopathic and heritable) pulmonary arterial hypertension

• Pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease

• Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology

Some improvements have also been shown in patients with pulmonary arterial hypertension WHO functional class II.

Bosentan tablets are also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

Bosentan Milpharm 125 mg film-coated tablets

Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:

• Primary (idiopathic and heritable) pulmonary arterial hypertension

• Pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease

• Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology

Some improvements have also been shown in patients with pulmonary arterial hypertension WHO functional class II.

Bosentan is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

Bosentan Milpharm 62.5 mg film-coated tablets

Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:

• Primary (idiopathic and heritable) pulmonary arterial hypertension

• Pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease

• Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology

Bosentan is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

Some improvements have also been shown in patients with pulmonary arterial hypertension WHO functional class II.

Bosentan Zentiva 125mg film-coated tablets

Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:

• Primary (idiopathic and heritable) PAH,

• PAH secondary to scleroderma without significant interstitial pulmonary disease,

• PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology.

Some improvements have also been shown in patients with PAH WHO functional class II.

Bosentan is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

Bosentan Zentiva 62.5 mg film-coated tablets

Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:

• Primary (idiopathic and heritable) PAH,

• PAH secondary to scleroderma without significant interstitial pulmonary disease,

• PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology.

Some improvements have also been shown in patients with PAH WHO functional class II.

Bosentan is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.